Open AccessClinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease
Author(s) -
Gaurav Goyal,
Mithun Vinod Shah,
Timothy G. Call,
Mark R. Litzow,
William J. Hogan,
Ronald S. Go
Publication year - 2017
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2017.0041
Subject(s) - medicine , cladribine , erdheim–chester disease , progressive disease , lesion , retrospective cohort study , disease , radiology , surgery , histiocytosis
While cladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also has activity against myeloid neoplasms, such as Erdheim-Chester disease (ECD).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom